

CURRICULUM VITAE

蘇文彬醫師 (Wen-Pin Su, M.D., Ph.D.)

Associate Professor (since 2017.8),

**Institute of Clinical Medicine & Departments of
Oncology and Internal Medicine,**

College of Medicine, National Cheng Kung University

Deputy Director, Cancer Center (since 2020.8),

National Cheng Kung University Hospital,

College of Medicine, National Cheng Kung University

Address: Rm 7010, No.35, Xiao-dong Road, Tainan 704, Taiwan (7F, Outpatient Building, NCKUH)

Tel: 06-2353535 ext. (O) 4252 (Lab) 6283

Email: wpsu@mail.ncku.edu.tw



ATTENDING PHYSICIAN:

Departments of Internal Medicine, NCKUH (since 2005.7)

Department of Oncology, NCKUH (sine 2020.9)

EDUCATION :

MD : School of Medicine, National Taiwan University; 1992.9 -1999.6

PhD : Institutes of Clinical Medicine, College of Medicine, NCKU. 2006. 9 – 2012.10

PROFESSIONAL TRAINING:

Clinical Lecturer: Department of Internal Medicine, NCKU; (2007.8 – 2013.1)

(Clinical) Assistant Professor: Department of Internal Medicine, NCKU; (2013.2 – 2017.7)

Assistant Professor: Institute of Clinical Medicine, NCKU; (2015.8 – 2017.7)

Sub-Specialty: Thoracic Oncology, GU Oncology; Bio-application of Nanoscience

MOST Funding: every year since 2008/8 including 2020/8 (Integrated grant proposal--MOST 109-2314-B-006-078: 3 years, and MOST 109-2314-B-006-084-MY3)

REFERRED PAPER (Recent 5 years)

1. Manoharan D, Chang LC, Shan YS, Wang LC, Lin FC, Wu LC, Sheu HS, **Su WP**, Yeh CS. Synchronization of Nanoparticle Sensitization and Radiosensitizing Chemotherapy through Cell Cycle Arrest Achieving Ultralow X-Ray Dose Delivery to Pancreatic Tumors. (**ACS Nano, accepted on 2021/5/3**) (IF=14.588, **Nanoscience & Nanotechnology: 9.7%**) (**Co-Corresponding author**)
2. Debele TA, Wu PC, Wei, YF, Chuang JY, Tsai, JH, **Su WP**. Targeted delivery of HSP90 inhibitor, AUY922, using GSH-sensitive Hyaluronic acid derivative-micelle to enhance therapeutic efficacy of brain cancers. (revision to Cancers.) (IF>6.0) (**Corresponding author**)
3. **Su WP**, Chang LC, Huang WH, Huang CC, Yeh CS. In situ ONPG-based glyco-condensation on Au nanoparticles formation tailors macrophage polarization for effective lung cancer therapy. submitted to JACS (IF=14.6) (**First and Co-Corresponding author**)

4. Debele TA, Yeh CF, **Su WP**. Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators. *Cancers* 2020; 12 (12): 3773 **(Corresponding author) (IF:6.126, Oncology: 15.2%)**
5. Debele TA, Wu HC, Wu SR, Shan YS, **Su WP**. Combination Delivery of Alpha-Tocopheryl Succinate and Curcumin Using a GSH-Sensitive Micelle (PAH-SS-PLGA) to Treat Pancreatic Cancer. *Pharmaceutics* 2020, 12 (8), 0778. **(Corresponding author) (IF:4.421, Pharmacology/Pharmacy: 16.3%)**
6. Chang LC, Wu SR, Wu CL, **Su WP**. Secreted protein acidic and rich in cysteine (SPARC), required for Rab-37 mediated exocytosis, promotes lung cancer metastasis via WNK1 activation. preparation to submit *Theranostics*. (IF: 8.7) **(Corresponding author)**
7. Shiu JL, Wu CK, Chang SB, Sun YJ, Chen YJ, Lai CC, Chiu WT, Chang WT, Myung K, **Su WP**, Liaw H. The HLTf-PARP1 interaction in the progression and stability of damaged replication forks caused by methyl methanesulfonate. *Oncogenesis*. 2020 Dec 7;9(12):104. **(Corresponding author) (IF:6.119, Oncology: 15.6%)**
8. Hsu LN, Tsai YS, Tsai HT, **Su WP**, Tong YC. Study on the pathophysiological mechanism responsible for lower urinary tract symptoms associated with prostate cancer using an animal model. *LUTS* 2020 Dec 31.doi: 10.1111/luts.12370. **(co-Corresponding author) (IF: 1.205, Urology & Nephrology: 85.9%)**
9. Pham KY, Wang LC, Hsieh CC, Hsu YP, Chang LC, **Su WP**, Chien YH, Yeh CS. 1550 nm excitation-responsive upconversion nanoparticles to establish dual-photodynamic therapy against pancreatic tumor. *Journal of Materials Chemistry B*. 2021 Jan, 9, 694-709. **(IF: 5.344, Materials Science, Biomaterials: 23.7%)**
10. Debele TA, **Su WP**. Polysaccharide and Protein-based functional wound dressing materials and applications. *International Journal of Polymeric Materials and Polymeric Biomaterials*. Published online: 08 Sep 2020. **(Corresponding author) (IF: 1.982 Polymer science: 59.3%)**
11. Petrylak DP, Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Flechon A, **Su WP**, et al. Overall survival of the randomised phase 3 RANGE trial: ramucirumab/docetaxel versus placebo/docetaxel in platinum-refractory, advanced urothelial carcinoma. *Lancet Oncology* 2020;21:105-120. **(IF: 33.752, 1.25%)**
12. Yen CC, Su HC, Chu CY, Lai SJ, Yan JJ, **Su WP**, Su WC. Correspondence: Excellent treatment response with Pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. *Lung Cancer* 2018; 120: 149-151 **(IF: 4.702, Respiratory System: 23%) (Corresponding author)**
13. Petrylak DP, Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Flechon A, **Su WP**, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. *Lancet*. 2017;390(10109):2266-2277. **(IF: 60.392, Medicine, General & Internal: 1.2%)**
14. **Su WP**, Ho YC, Wu CK, Shiu JL, Hsu SH, Huang JC, Yeh CF, Chang SB, Chiu WT, Hung JJ, Liu TL, Wu WS, Wu PY, Tsai MD, Chang JY, Su WC, Liaw H. Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. **(First & co-corresponding author; Sci Rep. 2017; 7(1):3879) (IF: 4.0) (Multidiscipline science: 24%)**
15. **Su WP**, Hsu SH, Chia LC, Lin JY, Jiang ZD, Lin YJ, Chen YC, Chang MS, Yang WB, Hung JJ, Hung PC, Wu WS, Myung K, Liaw H. Combined interactions of plant homeodomain 1 and chromodomain regulate NuA4 activity at DNA double-strand breaks. *Genetics* 202(1):77-92, 2016. **(IF: 4.015, Genetics and Heredity 27%)**
16. Hsu CY, Lin CH, Jan YH, Su CY, Yao YC, Cheng HC, Hsu TI, Wang PS, **Su WP**, Yang CJ, Huang MS, Calkins MJ, Hsiao M, Lu PJ. HIP1 is an Early-Stage Prognostic Biomarker of Lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated EMT. *Am J Respir Crit Care Med*. 193(8):869-880, 2016 **(IF: 17.452, Respiratory System: 3.1%)**